Grant: Engage Grants Program
University of Toronto
$25,000.00
Optimization of DENTAQ? probiotic for superior cavities prevention
FY 2016-17
Summary
Integra Medical Inc. is a commercialization stage biotechnology company with the vision to become a leading developer andinternational marketer of innovative probiotic-based, microbiome-modulating products and therapies with proven safety andefficacy. As a result of focused R&D efforts, pilot production, composition refinement, clinical validation and proof-of-concept / pilotcommercialization, Integra now owns two breakthrough natural health product platforms: one for gum inflammation, ear, nose, andthroat health; the other for preventing cavities and repairing tooth enamel - each of the conditions affecting over 90% of thepopulation worldwide. Our patent-pending anti-caries product, Dentaq? Dental Health Probiotic Complex, is the first and only inthe world to combine scientifically proven, synergistically acting probiotics for oral/dental health with a clinically proven toothenamel remineralization compound and therefore represents a novel, breakthrough class of synbiotic probiotic products. Theproposed project, led by Dr. Céline M. Lévesque, the only Research Chair in Oral Microbiology in Canada, engages worldrenownedoral microbiology and dental research experts to help optimize our multi-strain probiotic composition and take thecurrent work on our product's anti-caries mechanisms of action to the next level, using clinically relevant in vitro and ex vivomodels. This project will position Integra as a global player with high-growth commercialization potential via direct sales andlicensing and will support creation of high-quality jobs, and continued research and development, all of which will attractinvestment in Canada-based innovation and position Canada as the hub in dental research and microbiome-modulating productsand targeted therapies.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
505261-2016
Name nom
Levesque, Céline
Department département
Dentistry, Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
5200
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Microbiology
Research subject fr
Microbiologie
Partie
1
Nb partie
1
Application title
Optimization of DENTAQ? probiotic for superior cavities prevention
Keyword
NSERC
Application summary
Integra Medical Inc. is a commercialization stage biotechnology company with the vision to become a leading developer andinternational marketer of innovative probiotic-based, microbiome-modulating products and therapies with proven safety andefficacy. As a result of focused R&D efforts, pilot production, composition refinement, clinical validation and proof-of-concept / pilotcommercialization, Integra now owns two breakthrough natural health product platforms: one for gum inflammation, ear, nose, andthroat health; the other for preventing cavities and repairing tooth enamel - each of the conditions affecting over 90% of thepopulation worldwide. Our patent-pending anti-caries product, Dentaq? Dental Health Probiotic Complex, is the first and only inthe world to combine scientifically proven, synergistically acting probiotics for oral/dental health with a clinically proven toothenamel remineralization compound and therefore represents a novel, breakthrough class of synbiotic probiotic products. Theproposed project, led by Dr. Céline M. Lévesque, the only Research Chair in Oral Microbiology in Canada, engages worldrenownedoral microbiology and dental research experts to help optimize our multi-strain probiotic composition and take thecurrent work on our product's anti-caries mechanisms of action to the next level, using clinically relevant in vitro and ex vivomodels. This project will position Integra as a global player with high-growth commercialization potential via direct sales andlicensing and will support creation of high-quality jobs, and continued research and development, all of which will attractinvestment in Canada-based innovation and position Canada as the hub in dental research and microbiome-modulating productsand targeted therapies.